Amgen Inc
featured
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
» Read More
More
-
Amgen Inc. rose $2.16 or 2.1 percent, to $106.72. Biogen Idec rose $3.94 or 1.9 percent, to $213.22. Celgene Corp. rose $4.75 or 3.9 percent, to $127.46.
-
Amgen Inc. rose $1.29 or 1.2 percent, to $105.85. Biogen Idec rose $2.64 or 1.3 percent, to $211.92. Celgene Corp. rose $3.61 or 2.9 percent, to $126.32.
-
Amgen Inc. rose$. 64 or. 6 percent, to $105.20. Biogen Idec rose $1.99 or 1.0 percent, to $211.27. Celgene Corp. rose $2.02 or 1.6 percent, to $124.73.
-
Amgen Inc. fell$. 51 or. 5 percent, to $104.56. Biogen Idec fell $1.43 or. 7 percent, to $209.28. Celgene Corp. fell$. 03 or percent, to $122.71.
-
Amgen Inc. fell$. 09 or. 1 percent, to $104.98. Biogen Idec fell$. 72 or. 3 percent, to $209.99. Celgene Corp. rose$. 53 or. 4 percent, to $123.27.
-
Amgen Inc. fell$. 16 or. 2 percent, to $104.91. Biogen Idec fell$. 38 or. 2 percent, to $210.33. Celgene Corp. fell$. 44 or. 4 percent, to $122.30.
-
Amgen Inc. rose$. 61 or. 6 percent, to $105.07. Biogen Idec fell $1.84 or. 9 percent, to $210.71. Celgene Corp. rose $1.08 or. 9 percent, to $122.74.
-
Amgen Inc. rose$. 14 or. 1 percent, to $104.60. Biogen Idec fell$. 91 or. 4 percent, to $211.64. Celgene Corp. rose$. 81 or. 7 percent, to $122.47.
-
Amgen Inc. rose$. 44 or. 4 percent, to $104.90. Biogen Idec rose $1.23 or. 6 percent, to $213.78. Celgene Corp. rose $1.43 or 1.2 percent, to $123.09.
-
*Announces top-line results of vectibix phase 3 head-to-head. study against erbitux in metastatic colorectal cancer. *Says study meets primary endpoint of non-inferiority in monotherapy setting.
-
*Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Shares jump five-fold in two years, market value $26 bln. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
May 2- Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.
-
May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
-
May 1- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
-
**MERCK& CO INC, $44.76, down 5 pct. **TITAN PHARMACEUTICALS INC, $0.34, down 80 pct. U.S. health regulators rejected an experimental drug to treat opioid addiction made by Titan Pharmaceuticals and asked for additional data showing it works, the company said.
-
**MERCK& CO INC, $44.76, down 5 pct. **TITAN PHARMACEUTICALS INC, $0.34, down 80 pct. **NEUTRAL TANDEM INC, $4.12, up 38 pct.
-
Wall Street was set for a slightly lower open on Wednesday, weighed by weak results from Merck and as investors waited to hear from the U.S. **MERCK& CO INC, Tuesday close $47, down 5 pct premarket. **CHESAPEAKE ENERGY CORP, Tuesday close $19.54, up 5 pct premarket.